Clinican BEAD-T1D: Building the Evidence to Address Disengagement in Type 1 Diabetes (BEAD-T1D)

March 19, 2026 updated by: Ananta Addala, Stanford University

Improving Outcomes in Pediatric Diabetes: Building the Evidence Base to Inform Effective Diabetes Technology Interventions

Youth with public insurance underutilize diabetes care, particularly diabetes technology which is associated with improvement in diabetes-specific outcomes. Thus, we urgently need studies to understand and increase diabetes technology utilization. This proposed research will (1) address the gap in knowledge of barriers and promoters in youth working with clinicians to identify and address factors associated with diabetes technology uptake and utilization.

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Detailed Description

As diabetes technologies have become more innovative and effective in the management of pediatric type 1 diabetes (T1D), research and usage has not engaged all youth living with T1D . Studies have consistently demonstrated lower rates of diabetes technology use in some youth. Although diabetes technology has the potential to improve in pediatric T1D outcomes. This proposal aims to build an evidence base for data-driven interventions designed to increase uptake and utilization of diabetes innovations by addressing barriers and supporting promoters of diabetes technology use. Focusing on clinicians, the overall objective of this proposal is to test a brief pilot intervention to increase provider recommendation of diabetes technology.

Study Type

Interventional

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • age 18+ years, providers who care for youth with T1D for at least 50% of their clinical efforts, practicing in the United States, care for youth with public insurance, health care role of physicians, advanced practice providers, or certified diabetes care & education specialists, and understand and willingness to follow study protocol.

Exclusion Criteria:

  • significant cognitive impairment or medical or psychiatric condition that would interfere with participation in the study or lack of access to a smartphone or Wi-Fi via computer.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pilot Intervention
The design for this phase is a prospective pilot study. The intervention will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will evaluate rates of diabetes technology utilization. Virtual delivery of the pilot intervention will facilitate national recruitment.
Behavioral: Intervention to increase diabetes technology prescriptions
The design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. We will recruit 20 clinicians to participate in the delivery of the pilot intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tracking people who complete the study
Time Frame: Through study completion, an average of one year
The investigators will also keep track of who enrolled in the study and track how many people completed the intervention.
Through study completion, an average of one year
Interviews with you on your feedback on the intervention
Time Frame: Within 4 weeks upon intervention completion
The investigators will ask clincians questions in a 30-minute interview at the end of the four-week intervention. The investigators will evaluate feedback on ways the intervention could be more effective and what changes can be made to the intervention so that it is most effective. The investigators will ask clinicians if you they likely to change diabetes management after completing the intervention.
Within 4 weeks upon intervention completion
Survey questions on your feedback on the intervention
Time Frame: Within 4 weeks upon intervention completion
The investigators will ask clincians questions in a feedback survey at the end of the four-week intervention. These questions will be developed by the investigators and will ask ways the intervention could be more effective and what changes can be made to the intervention so that it is most effective. Example questions of what the investigators plan to ask in the survey include: - Was the study explained appropriately? - Was it logistically easy to participate in the study? How could it have improved? - What parts of the intervention were most helpful? - What parts could be cut? - What parts need to be added? - Are there certain types of people who are likely to do better with this intervention?
Within 4 weeks upon intervention completion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in diabetes technology usage
Time Frame: Within 4 weeks upon intervention completion
The investigators will ask you survey questions to understand clinician attitudes towards diabetes technology at the start and end of the study intervention. The investigators will use a validated survey measure called Diabetes Technology Attitudes Survey to assess this in addition to having conversations with clinicians to learn beliefs about diabetes technology.
Within 4 weeks upon intervention completion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Stanford University

Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 15, 2025

Primary Completion (Estimated)

September 15, 2026

Study Completion (Estimated)

September 30, 2026

Study Registration Dates

First Submitted

May 20, 2025

First Submitted That Met QC Criteria

March 19, 2026

First Posted (Actual)

March 24, 2026

Study Record Updates

Last Update Posted (Actual)

March 24, 2026

Last Update Submitted That Met QC Criteria

March 19, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 65313P
  • K23DK131342 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 1 Diabetes (T1D)

Clinical Trials on Intervention to increase diabetes technology prescriptions

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe